This understanding of the mechanism of action of K1-70TM is helpful in developing applications for its use in controlling activation of the TSHR in Graves’ disease (Furmaniak et al. 2022), in Graves’ orbitopathy (Furmaniak et al. 2022) and in thyroid cancer (Ryder et al. 2021). Here, TSHR is linked to Graves ophthalmopathy.